Literature DB >> 19273699

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

René Adam1, Dennis A Wicherts, Robbert J de Haas, Oriana Ciacio, Francis Lévi, Bernard Paule, Michel Ducreux, Daniel Azoulay, Henri Bismuth, Denis Castaing.   

Abstract

PURPOSE: Although oncosurgical strategies have demonstrated increased survival in patients with unresectable colorectal liver metastases (CLM), their potential for cure is still questioned. The aim of this study was to evaluate long-term outcome after combining downsizing chemotherapy and rescue surgery and to define prognostic factors of cure. PATIENTS AND METHODS: All patients with initially unresectable CLM who underwent rescue surgery and had a minimum follow-up of 5 years were included. Cure was defined as a disease-free interval > or = 5 years from last hepatic or extrahepatic resection until last follow-up.
RESULTS: Mean age of 184 patients who underwent resection (April 1988 through July 2002) was 56.9 years. Patients had a mean number of 5.3 metastases (bilobar in 76%), associated to extrahepatic disease in 27%. Surgery was possible after one (74%) or more (26%) lines of chemotherapy. Five- and 10-year overall survival rates were 33% and 27%, respectively. Of 148 patients with a follow-up > or = 5 years, 24 patients (16%) were considered cured (mean follow-up, 118.6 months), six (25%) of whom were considered cured after repeat resection of recurrence. Twelve "cured" patients (50%) had a disease-free interval more than 10 years. Cured patients more often had three or fewer metastases less than 30 mm (P = .03) responding to first-line chemotherapy (P = .05). Multivariate analysis identified maximum size of metastases less than 30 mm at diagnosis, number of metastases at hepatectomy three or fewer, and complete pathologic response as independent predictors of cure.
CONCLUSION: Cure can be achieved overall in 16% of patients with initially unresectable CLM resected after downsizing chemotherapy. In addition to increased survival, this oncosurgical approach has real potential for disease eradication.

Entities:  

Mesh:

Year:  2009        PMID: 19273699     DOI: 10.1200/JCO.2008.19.9273

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  157 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  The role of 18FDG PET/CT in the management of colorectal liver metastases.

Authors:  Alec H Engledow; James R A Skipworth; Farrokh Pakzad; Charles Imber; Peter J Ell; Ashley M Groves
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

3.  Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Authors:  F Petrelli; S Barni
Journal:  Int J Colorectal Dis       Date:  2012-02-23       Impact factor: 2.571

Review 4.  What can we learn from oncology surgical trials?

Authors:  Serge Evrard; Pippa McKelvie-Sebileau; Cornelis van de Velde; Bernard Nordlinger; Graeme Poston
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

5.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 6.  [Surgical innovations in treatment of metastatic colorectal cancer : Complexity of metastatic surgery as example for personalized medicine].

Authors:  C Hackl; S M Brunner; K M Schmidt; H J Schlitt
Journal:  Chirurg       Date:  2018-03       Impact factor: 0.955

Review 7.  [What can colorectal cancer centers achieve in the diagnostics and therapy of colorectal liver metastases?].

Authors:  S Wesselmann; T Seufferlein
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

8.  Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.

Authors:  Po-Chen Chu; Peng-Chan Lin; Hsing-Yu Wu; Kuen-Tyng Lin; Christina Wu; Tanios Bekaii-Saab; Yih-Jyh Lin; Chung-Ta Lee; Jeng-Chang Lee; Ching-Shih Chen
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

9.  Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy.

Authors:  Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

10.  Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival.

Authors:  Francesco Ardito; Maria Vellone; Alessandra Cassano; Agostino M De Rose; Carmelo Pozzo; Alessandro Coppola; Bruno Federico; Ivo Giovannini; Carlo Barone; Gennaro Nuzzo; Felice Giuliante
Journal:  J Gastrointest Surg       Date:  2012-12-08       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.